PFBT
ACAD icon

Parkside Financial Bank & Trust’s Acadia Pharmaceuticals ACAD Stock Holding History

Parkside Financial Bank & Trust’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.82K Sell
309
-62
-17% -$1.36K ﹤0.01% 1742
2026
Q1 		$8.26K Buy
371
+22
+6% +$526 ﹤0.01% 1653
2025
Q4 		$9.32K Buy
349
+35
+11% +$836 ﹤0.01% 1599
2025
Q3 		$6.7K Buy
314
+7
+2% +$166 ﹤0.01% 1654
2025
Q2 		$6.62K Buy
307
+217
+241% +$4.03K ﹤0.01% 1619
2025
Q1 		$1.5K Buy
+90
New +$1.64K ﹤0.01% 1970
2021
Q2 		– Sell
-4
Closed – – 1701
2021
Q1 		$0 Hold
4
– – ﹤0.01% 1666
2020
Q4 		$0 Buy
+4
New +$199 ﹤0.01% 1591
2020
Q3 		– Sell
-245
Closed -$12K – 1505
2020
Q2 		$12K Buy
+245
New +$11.8K ﹤0.01% 763
2018
Q2 		– Sell
-74
Closed -$2K – 1516
2018
Q1 		$2K Hold
74
– – ﹤0.01% 973
2017
Q4 		$2K Sell
74
-52
-41% -$1.66K ﹤0.01% 946
2017
Q3 		$5K Hold
126
– – ﹤0.01% 834
2017
Q2 		$4K Hold
126
– – ﹤0.01% 882
2017
Q1 		$4K Hold
126
– – ﹤0.01% 850
2016
Q4 		$4K Sell
126
-48
-28% -$1.27K ﹤0.01% 852
2016
Q3 		$6K Hold
174
– – ﹤0.01% 806
2016
Q2 		$6K Buy
174
+55
+46% +$1.84K ﹤0.01% 782
2016
Q1 		$3K Buy
+119
New +$2.6K ﹤0.01% 838

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Parkside Financial Bank & Trust's ACAD Position: Q2 2026 in Review

Parkside Financial Bank & Trust reduced its Acadia Pharmaceuticals (ACAD) stake by 17% in Q2 2026, selling an estimated $1.36K and leaving 309 shares worth $7.82K. The position accounts for ﹤0.01% of the portfolio, ranked #1742.

Parkside Financial Bank & Trust first reported a position in ACAD in Q1 2016 and has held it in 18 quarters since. The position peaked at $12K in Q2 2020. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Parkside Financial Bank & Trust held 309 shares of Acadia Pharmaceuticals worth $7.82K as of Q2 2026.
  • Parkside Financial Bank & Trust sold 62 Acadia Pharmaceuticals shares in Q2 2026, an estimated $1.36K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #1742 holding.
  • Parkside Financial Bank & Trust first reported a position in Acadia Pharmaceuticals in Q1 2016 and has held it in 18 quarters since.
  • Parkside Financial Bank & Trust's Acadia Pharmaceuticals position peaked at $12K in Q2 2020.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.